[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100502915":3},{"organization":4,"armGroups":7,"interventions":34,"overallOfficials":60,"centralContacts":65,"locations":75,"responsibleParty":135,"collaborators":40,"id":137,"slug":138,"hasResults":139,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":40,"eligibilityCriteria":143,"healthyVolunteers":139,"sex":144,"minAge":145,"maxAge":40,"enrollmentInfo":146,"targetDuration":40,"studyType":149,"phases":150,"briefSummary":152,"conditions":153,"keywords":40,"overallStatus":78,"whyStopped":40,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},{"fullName":5,"class":6},"Onward Therapeutics","INDUSTRY",[8,14,19,24,29],{"label":9,"type":10,"description":11,"interventionNames":12},"OT-A201 monotherapy","EXPERIMENTAL","OT-A201 administered by IV infusion on a weekly (qw) basis. An alternative dosing schedule of every 2 weeks (q2w) may be implemented based on the clinical safety and laboratory data.",[13],"Drug: OT-A201",{"label":15,"type":10,"description":16,"interventionNames":17},"OT-A201 in combination with iMiD","OT-A201 in combination with lenalidomide or pomalidomide at the approved dose",[13,18],"Drug: IMids",{"label":20,"type":10,"description":21,"interventionNames":22},"OT-A201 in combination with a specific agent","OT-A201 in combination with late stage approved treatment (combination to be defined by a protocol amendment)",[13,23],"Drug: TBD Compound",{"label":25,"type":10,"description":26,"interventionNames":27},"OT-A201 in combination with bevacizumab","OT-A201 in combination with bevacizumab at the approved dose",[13,28],"Drug: Bevacizumab",{"label":30,"type":10,"description":31,"interventionNames":32},"OT-A201 in combination with paclitaxel","OT-A201 in combination with paclitaxel at the approved dose",[13,33],"Drug: Paclitaxel",[35,41,48,52,56],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"DRUG","OT-A201","OT-A201 IV infusion qw or q2w",[20,25,15,30,9],null,{"type":36,"name":42,"description":43,"armGroupLabels":44,"otherNames":45},"IMids","Combination regimen for hematological malignancy Lenalidomide: 25 mg on Days 1 to 21 of each 28-day cycle; or Pomalidomide: 4 mg on Days 1 to 21 of each 28-day cycle",[15],[46,47],"lenalidomide","pomalidomide",{"type":36,"name":49,"description":50,"armGroupLabels":51,"otherNames":40},"Bevacizumab","Combination regimen for solid tumor Bevacizumab: 10 mg\u002Fm² q2w",[25],{"type":36,"name":53,"description":54,"armGroupLabels":55,"otherNames":40},"Paclitaxel","Combination regimen for solid tumor Paclitaxel: 175 mg\u002Fm² q3w",[30],{"type":36,"name":57,"description":58,"armGroupLabels":59,"otherNames":40},"TBD Compound","Combination regimen for hematological malignancy",[20],[61],{"name":62,"affiliation":63,"role":64},"Eric Raymond, MD, PhD","Saint-Joseph Hospital - Paris","PRINCIPAL_INVESTIGATOR",[66,71],{"name":67,"role":68,"phone":69,"phoneExt":40,"email":70},"Bruno Piccolella","CONTACT","+33 6 12 97 73 68","bruno.piccolella@onward-therapeutics.com",{"name":72,"role":68,"phone":73,"phoneExt":40,"email":74},"Erica Wang","+886 921 865 855","erica.wang@onward-therapeutics.com",[76,95,107,120],{"facility":77,"status":78,"city":79,"state":40,"zip":40,"country":80,"countryCode":81,"cosmosGeoPoint":82,"geoPoint":87,"contacts":88},"ICM - Montpellier","RECRUITING","Montpellier","France","FR",{"type":83,"coordinates":84},"Point",[85,86],3.87635,43.61093,{"lat":86,"lon":85},[89,93],{"name":90,"role":68,"phone":91,"phoneExt":40,"email":92},"Jérémy Fleith","+33 (0)4 67 61 85 70","Jeremy.Fleith@icm.unicancer.fr",{"name":94,"role":64,"phone":40,"phoneExt":40,"email":40},"Diego Tosi, MD",{"facility":96,"status":78,"city":79,"state":40,"zip":40,"country":80,"countryCode":81,"cosmosGeoPoint":97,"geoPoint":99,"contacts":100},"Saint-Eloi Hospital - Montpellier (CHU)",{"type":83,"coordinates":98},[85,86],{"lat":86,"lon":85},[101,105],{"name":102,"role":68,"phone":103,"phoneExt":40,"email":104},"Cécile Popko","+33 (0)4 67 33 24 13","c-popko@chu-montpellier.fr",{"name":106,"role":64,"phone":40,"phoneExt":40,"email":40},"Guillaume Cartron, MD, PhD",{"facility":63,"status":78,"city":108,"state":40,"zip":40,"country":80,"countryCode":81,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"Paris",{"type":83,"coordinates":110},[111,112],2.3488,48.85341,{"lat":112,"lon":111},[115,119],{"name":116,"role":68,"phone":117,"phoneExt":40,"email":118},"Sandrine Rullé","+33 (0)1 44 12 32 41","srulle@ghpsj.fr",{"name":62,"role":64,"phone":40,"phoneExt":40,"email":40},{"facility":121,"status":78,"city":122,"state":40,"zip":40,"country":80,"countryCode":81,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"Centre Eugène Marquis","Rennes",{"type":83,"coordinates":124},[125,126],-1.67431,48.11109,{"lat":126,"lon":125},[129,133],{"name":130,"role":68,"phone":131,"phoneExt":40,"email":132},"Emilie Fouchet","+33 (0)2 99 25 44 09","e.fouchet@rennes.unicancer.fr",{"name":134,"role":64,"phone":40,"phoneExt":40,"email":40},"Héloise Bourien, MD",{"type":136,"investigatorFullName":40,"investigatorTitle":40,"investigatorAffiliation":40,"oldNameTitle":40,"oldOrganization":40},"SPONSOR","100502915","phase-1-first-in-human-study-of-ot-a201-in-patients-with-selected-hematological-malignancies-and-solid-tumors-100502915",false,"NCT05828459","First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors","A First-in-human, Dose-escalation Followed by Expansion Study to Assess the Safety and Preliminary Efficacy of a Bispecific Antibody OT-A201 as Monotherapy and in Combination Therapy in Patients With Selected Hematological Malignancies and Solid Tumors","Main Inclusion Criteria:\n\n* Histologically or cytologically confirmed relapsed\u002Frefractory hematological malignancy or advanced\u002Fmetastatic solid cancer\n* Measurable disease\n* Have had all available therapeutic standards for their disease\n* Willingness to undergo baseline biopsy\u002Fbone marrow aspiration in case biopsy was not collected after completion of the most recent prior therapy\n* ECOG performance status ≤ 1\n* Life expectancy \\> 3 months as assessed by the investigator\n* Acceptable clinical lab results\n\nMain Exclusion Criteria:\n\n* Systemic steroids at a daily dose of \\> 10 mg of prednisone or equivalent within 28 days before study treatment. Transient use of steroids for other medical condition may be allowed\n* Ongoing immune-related adverse events irAEs and or AEs ≥ grade 2 from previous therapies not resolved except vitiligo, stable neuropathy up to grade 2, hair loss, and stable endocrinopathies with substitutive hormone therapy\n* Within 4 weeks of major surgery\n* Documented history of active autoimmune disorder requiring systemic immunosuppressive therapy within the last 12 months\n* Prior solid organ transplant\n* Primary or secondary immune deficiency\n* Active and uncontrolled infection requiring intravenous antibiotic or antiviral treatment\n* Seropositive (except after vaccination or confirmed cure for hepatitis) for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)\n* Clinically significant disease","ALL","18 Years",{"count":147,"type":148},150,"ESTIMATED","INTERVENTIONAL",[151],"PHASE1","This phase 1 study is aimed at establishing the safety basis of OT-A201 in the treatment of hematological malignancies and solid tumors. In the dose of escalation part it is to characterize the overall safety and tolerability profile and determine the recommended dose(s) of OT-A201 as monotherapy, and in various combination regimens. Preliminary information about anti-cancer activity will be further explored in the expansion part of the study.",[154,155],"Hematological Malignancy","Solid Tumor","2025-03-17",{"date":158,"type":159},"2025-03-20","ACTUAL",{"date":161,"type":159},"2023-07-10",{"date":163,"type":148},"2027-07",{"name":5,"class":6},4]